Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Summary

This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.

Timeline

Start

2018-07-01

Primary completion

2026-03-03

Completion

2026-03-03

Drugs

Indications